News Activity: Dr. Reddy’s Laboratories (NYSE:RDY), Gilead Sciences (NASDAQ:GILD), Hardinge (NASDAQ:HDNG), Bio-Path Holdings (NASDAQ:BPTH), Equifax (NYSE:EFX)

Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) shares decreased -0.64% in last trading session and ended the day at $45.19. RDY Gross Margin is 59.20% and its has a return on assets of 12.10%. Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) quarterly performance is -3.38%.

Dr. Reddy’s Laboratories (NYSE: RDY) announced that it has entered into a licensing agreement with Eisai Co., Ltd, Japan by which Dr. Reddy’s will be granted exclusive worldwide development and commercialization rights (excluding Japan and Asia) for Eisai’s investigational anticancer agent E7777. Eisai will be responsible for the development and marketing of E7777 in Japan and Asia, while Dr. Reddy’s holds the option for rights to develop and market the agent in India.

Gilead Sciences Inc. (NASDAQ:GILD) ended the last trading day at $91.86. Company weekly volatility is calculated as 2.33% and price to cash ratio as 8.60. Gilead Sciences Inc. (NASDAQ:GILD) showed a weekly performance of 1.98%.

Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has submitted a New Drug Application (NDA) to Japan’s Pharmaceutical and Medical Devices Agency (PMDA) for tenofovir alafenamide (TAF) 25 mg, an investigational once-daily treatment for adults with chronic hepatitis B virus (HBV) infection.

On 31 March, Hardinge Inc. (NASDAQ:HDNG) shares decreased -0.80% and was closed at $12.47. HDNG EPS growth in last 5 year was 19.50%. Hardinge Inc. (NASDAQ:HDNG) year to date (YTD) performance is 34.10%.

On March 24, 2016, Douglas A. Greenlee resigned as a director of Hardinge Inc. (NASDAQ:HDNG), effective immediately due to health reasons. Mr. Greenlee’s resignation from the Company’s Board of Directors was not the result of any disagreement with the Company or for any of the other reasons requiring further disclosure under Item 5.02(a) of Form 8-K. The Company thanks Mr. Greenlee for his many years of service to the Company.

Bio-Path Holdings, Inc. (NASDAQ:BPTH) shares moved up 6.58% in last trading session and ended the day at $2.59. BPTH has a return on assets of -44.00%. Bio-Path Holdings, Inc. (NASDAQ:BPTH) quarterly performance is 85.00%.

On 23 March, Bio-Path Holdings, Inc., (NASDAQ:BPTH) announced that it has entered a sponsored research agreement with The University of Texas Southwestern Medical Center (UT Southwestern) to evaluate Bio-Path’s clinical pipeline for its efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. SLE is a chronic autoimmune disorder that presents an array of symptoms, including skin lesions, heart inflammation, joint pain, kidney failure and neuropsychiatric disorders. Included in the evaluation will be BP1001 (Liposomal Grb2 antisense), Bio-Path’s lead product candidate, which is currently in a Phase II study for blood cancers.

Equifax Inc. (NYSE:EFX) caters to the Financial space. It has a net profit margin of 16.10% and weekly performance is 2.47%. On the last day of trading company shares ended up at $114.29. Equifax Inc. (NYSE:EFX) distance from 50-day simple moving average (SMA50) is 8.92%.

On 29 March, Equifax Inc. (NYSE: EFX) has issued several resources to help organizations combat the elusive and increasingly expensive problem of fraud during customer acquisition. The resources describe current fraud scenarios, the background and methods most commonly used to commit this type of fraud, and outline best practices to detect and deter fraud during customer acquisition.